Prescribing Habits for Androgenetic Alopecia Among Dermatologists in Spain in 2024: A Cross-Sectional Study

    March 2026 in “ Actas Dermo-Sifiliográficas ”
    C. Pindado-Ortega, D. Saceda-Corralo, Á. Hermosa-Gelbard, J. Jiménez-Cauhé, M. González-Ramos, S. Vaño-Galvan
    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Spironolactone →

    powerful topical and oral anti-androgen used mostly by women

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Studysummary In this study, dermatologists in Spain reported a shift in androgenetic alopecia treatment practices from 2019-2020 to 2024, with increased prescribing of oral minoxidil and oral dutasteride, and changes in antiandrogen choices for different patient groups. Our plain-language summary of this paper — not a Tressless recommendation.
    A recent study surveyed 202 dermatologists in Spain to assess current prescribing habits for androgenetic alopecia (AGA) compared to 2019–2020. The findings indicate a significant shift towards oral minoxidil as the most prescribed treatment for AGA across all patient groups, with 89.1% for male AGA, 92.1% for premenopausal female AGA, and 93.1% for postmenopausal female AGA. Additionally, oral dutasteride has overtaken finasteride as the preferred antiandrogen for male AGA, while spironolactone is now favored for premenopausal AGA. For postmenopausal AGA, dutasteride has become the leading antiandrogen, replacing finasteride. This reflects evolving trends in AGA management and the growing acceptance of these treatments.
    Discuss this study in the Community →